http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Greg Sukay Joins Arcutis as Vice President of Manufacturing and Process Technologies
-
Greg Sukay Joins Arcutis as Vice President of Manufacturing and Process Technologies
-
Arcutis Biotherapeutics Inc. (ARQT) Names Sue-Jean Lin to Board
-
Arcutis Biotherapeutics Inc. (ARQT) Appoints Sue-Jean Lin to its Board
-
Arcutis Announces Appointment of Sue-Jean Lin to Board of Directors
-
Arcutis Announces Appointment of Sue-Jean Lin to Board of Directors
-
Rajvir Madan Joins Arcutis as Chief Digital and Information Officer
-
Rajvir Madan Joins Arcutis as Chief Digital and Information Officer
-
Arcutis Biotherapeutics Inc. (ARQT) Showcases Pivotal DERMIS-1 and -2 Phase 3 Trial Data for Topical Roflumilast Cream (ARQ-151) in Plaque Psoriasis at EADV Spring Symposium 2021
-
Arcutis Biotherapeutics Showcases Pivotal DERMIS-1 and -2 Phase 3 Trial Data for Topical Roflumilast Cream (ARQ-151) in Plaque Psoriasis at EADV Spring Symposium 2021
-
Arcutis Announces First Quarter 2021 Financial Results and Provides Business Update
-
Arcutis to Present New Roflumilast Cream Phase 3 Data at The European Academy of Dermatology and Venereology (EADV) Spring Symposium
-
Arcutis to Present New Roflumilast Cream Phase 3 Data at The European Academy of Dermatology and Venereology (EADV) Spring Symposium
-
Arcutis to Present at the 2021 Truist Securities Life Sciences Summit
-
Arcutis Biotherapeutics Inc. (ARQT) Showcases New Roflumilast Data in Psoriasis and Seborrheic Dermatitis at American Academy of Dermatology
-
Arcutis Biotherapeutics Showcases New Roflumilast Data in Psoriasis and Seborrheic Dermatitis at American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2021
-
Arcutis Biotherapeutics Showcases New Roflumilast Data in Psoriasis and Seborrheic Dermatitis at American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2021
-
Arcutis Biotherapeutics to Present New Roflumilast Data at The American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX)
-
Arcutis Biotherapeutics to Present New Roflumilast Data at The American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX)
-
Arcutis Biotherapeutics Inc. (ARQT) Begins Phase 3 Clinical Trial of Topical Roflumilast Cream (ARQ-151)
-
Arcutis Initiates Phase 3 Clinical Trial of Topical Roflumilast Cream (ARQ-151) as a Potential Treatment for Atopic Dermatitis in Pediatric Patients Between the Ages of Two and Five Years
-
Arcutis Initiates Phase 3 Clinical Trial of Topical Roflumilast Cream (ARQ-151) as a Potential Treatment for Atopic Dermatitis in Pediatric Patients Between the Ages of Two and Five Years
-
Arcutis Announces Updates to its Executive Team
-
Arcutis Announces Updates to its Executive Team
-
Arcutis Announces First Patient Enrolled in Phase 2a Clinical Trial Evaluating ARQ-252 as a Potential Treatment for Vitiligo
-
Arcutis Announces First Patient Enrolled in Phase 2a Clinical Trial Evaluating ARQ-252 as a Potential Treatment for Vitiligo
-
Arcutis Biotherapeutics to Showcase Long-term Safety, Efficacy, and Patient-Reported Outcomes of Roflumilast Cream for Chronic Plaque Psoriasis at Innovations in Dermatology: Virtual Spring Conference
-
Arcutis Biotherapeutics to Showcase Long-term Safety, Efficacy, and Patient-Reported Outcomes of Roflumilast Cream for Chronic Plaque Psoriasis at Innovations in Dermatology: Virtual Spring Conference
-
Arcutis to Present at the Cowen 41st Annual Health Care Conference
-
Arcutis to Present at the Cowen 41st Annual Health Care Conference
-
Courtney Barton Joins Arcutis as Chief Compliance Officer and Chief of Staff
-
Courtney Barton Joins Arcutis as Chief Compliance Officer and Chief of Staff
-
Arcutis Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
-
Arcutis Biotherapeutics Inc. (ARQT) Announces Positive Topline Results from Pivotal DERMIS-1 and -2 Phase 3 Trials of Topical Roflumilast Cream in Plaque Psoriasis
-
Arcutis Announces Positive Topline Results from Pivotal DERMIS-1 and -2 Phase 3 Trials of Topical Roflumilast Cream (ARQ-151) in Plaque Psoriasis
-
Arcutis to Advance Topical Roflumilast Foam (ARQ-154) into Phase 3 Development for the Treatment of Seborrheic Dermatitis
-
Arcutis Biotherapeutics Inc. (ARQT) Begins Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast Cream (ARQ-151)
-
Arcutis Initiates Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast Cream (ARQ-151) as a Potential Treatment for Atopic Dermatitis
-
Matthew Moore Joins Arcutis as Chief Business Officer
-
Arcutis Biotherapeutics Inc. (ARQT) Added to Nasdaq Biotechnology Index
-
Arcutis Biotherapeutics Added to Nasdaq Biotechnology Index
-
Arcutis Highlights Advanced Pipeline & Unique Immuno-Dermatology Drug Development Capabilities at Virtual Investor Day on December 9, 2020
-
Arcutis Announces Last Patient Completes Final Study Visit in DERMIS-1 and DERMIS-2 Pivotal Phase 3 Clinical Trials Evaluating ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque P
-
Arcutis to Host Virtual Investor Day on Wednesday, December 9, 2020
-
Data from Long-Term Safety Study Support Chronic Use of ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque Psoriasis
-
Arcutis Biotherapeutics (ARQT) Announces Positive Topline Data from Phase 2b Study of ARQ-154 (Topical Roflumilast Foam) as Potential Treatment for Scalp and Body Psoriasis
-
Arcutis Announces Positive Topline Data from Phase 2b Study of ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Scalp and Body Psoriasis
-
Arcutis Biotherapeutics to Present at the Stifel 2020 Virtual Healthcare Conference
-
Arcutis Announces Third Quarter 2020 Financial Results and Provides Business Update
-
Arcutis Announces Appointment of Terrie Curran to Board of Directors
